A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Background ：Under the pandemic of coronavirus disease 2019 (COVID-19), in addition to all trans retinoic acid (ATRA) and oral arsenic(RIF), high-risk acute promyelocytic leukemia (APL) patients might lack of the necessity of intravenous cytotoxic chemotherapy infusions timely. Therefore, there is an urgent need for an oral, efficient and safe regimen for high-risk APL.